LENZ 生物制药公司研发视觉治疗产品, 获得六位分析家一致的“Buy”评分。 Biopharmaceutical firm LENZ Therapeutics, developing vision therapy products, receives a consensus "Buy" rating from six analysts.

LENZ Therapeutics是一家专门从事视觉治疗的生物制药公司，获得了六位分析师的一致“买入”评级，包括Piper Sandler的“增持”和HC Wainwright的“买入”评级，12个月的平均目标价为35.00美元。 LENZ Therapeutics, a biopharmaceutical firm specializing in vision therapy, received a consensus "Buy" rating from six analysts, including "Overweight" from Piper Sandler and "Buy" from HC Wainwright, with average 12-month price targets at $35.00. 伦兹公司的产品LNZ100和LNZ101正在临床试验的第三阶段治疗长视. LENZ's products LNZ100 and LNZ101 are in Phase III clinical trials for presbyopia treatment. 机构投资者持有公司股份的54.32%。 Institutional investors hold 54.32% of the company's shares.